中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (12): 1033-1040.doi: 10.35541/cjd.20220608
中国医师协会皮肤科医师分会带状疱疹专家共识工作组 国家皮肤与免疫疾病临床医学研究中心
收稿日期:
2022-08-30
修回日期:
2022-10-11
发布日期:
2022-12-05
通讯作者:
李若瑜
E-mail:mycolab@126.com
Consensus Workgroup on Herpes Zoster, China Dermatologist Association; National Clinical Research Center for Skin and Immune Diseases
Received:
2022-08-30
Revised:
2022-10-11
Published:
2022-12-05
Contact:
Li Ruoyu
E-mail:mycolab@126.com
摘要: 【摘要】 带状疱疹是水痘-带状疱疹病毒再激活引起的感染性皮肤病,以皮肤损害和神经病理性疼痛为主要表现。本共识在2018版带状疱疹中国专家共识基础上,针对国内带状疱疹临床诊疗中存在的问题,特别是在治疗药物的选择、特殊人群及特殊类型处理、带状疱疹后神经痛等并发症的处置以及对疫苗预防接种的认识等方面进行综合分析和评价,提出诊疗建议,希望能够更好地指导带状疱疹的临床规范化诊治。
中国医师协会皮肤科医师分会带状疱疹专家共识工作组 国家皮肤与免疫疾病临床医学研究中心. 中国带状疱疹诊疗专家共识(2022版)[J]. 中华皮肤科杂志, 2022,55(12):1033-1040. doi:10.35541/cjd.20220608
Consensus Workgroup on Herpes Zoster, China Dermatologist Association, National Clinical Research Center for Skin and Immune Diseases. Chinese consensus on the diagnosis and management of herpes zoster (2022)[J]. Chinese Journal of Dermatology, 2022, 55(12): 1033-1040.doi:10.35541/cjd.20220608
[1] | 中国医师协会皮肤科医师分会带状疱疹专家共识工作组. 带状疱疹中国专家共识[J]. 中华皮肤科杂志, 2018,51(6):403⁃408. doi: 10.3760/cma.j.issn.0412⁃4030.2018.06.001. |
[2] | Bao L, Wei G, Gan H, et al. Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine[J]. Exp Ther Med, 2016,11(5):1788⁃1794. doi: 10.3892/etm.2016.3086. |
[3] | Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella⁃zoster virus infections[J]. Eur J Clin Microbiol Infect Dis, 2016,35(5):723⁃734. doi: 10.1007/s10096⁃016⁃2605⁃0. |
[4] | Alles S, Smith PA. Etiology and pharmacology of neuropathic pain[J]. Pharmacol Rev, 2018,70(2):315⁃347. doi: 10.1124/pr. 117.014399. |
[5] | Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective[J/OL]. BMJ Open, 2014,4(6):e004833. doi: 10.1136/bmjopen⁃2014⁃004833. |
[6] | Chen LK, Arai H, Chen LY, et al. Looking back to move forward: a twenty⁃year audit of herpes zoster in Asia⁃Pacific[J]. BMC Infect Dis, 2017,17(1):213. doi: 10.1186/s12879⁃017⁃2198⁃y. |
[7] | Kawai K, Yawn BP, Wollan P, et al. Increasing incidence of herpes zoster over a 60⁃year period from a population⁃based study[J]. Clin Infect Dis, 2016,63(2):221⁃226. doi: 10.1093/cid/ciw296. |
[8] | Tseng HF, Bruxvoort K, Ackerson B, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥ 50 years old: incidence, complications, hospitalization, mortality, and recurrence[J]. J Infect Dis, 2020,222(5):798⁃806. doi: 10. 1093/infdis/jiz652. |
[9] | van Oorschot D, Vroling H, Bunge E, et al. A systematic literature review of herpes zoster incidence worldwide[J]. Hum Vaccin Immunother, 2021,17(6):1714⁃1732. doi: 10.1080/21645 515.2020.1847582. |
[10] | 邓慧杰, 刘芳勋. 我国带状疱疹流行病学特征及疫苗免疫规划研究进展[J]. 中国继续医学教育, 2021,13(19):135⁃138. doi: 10.3969/j.issn.1674⁃9308.2021.19.039. |
[11] | Yenikomshian MA, Guignard AP, Haguinet F, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients[J]. BMC Infect Dis, 2015,15:106. doi: 10.1186/s12879⁃015⁃0810⁃6. |
[12] | Grabar S, Tattevin P, Selinger⁃Leneman H, et al. Incidence of herpes zoster in HIV⁃infected adults in the combined antiretroviral therapy era: results from the FHDH⁃ANRS CO4 cohort[J]. Clin Infect Dis, 2015,60(8):1269⁃1277. doi: 10.1093/cid/ciu1161. |
[13] | Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune⁃mediated diseases: a systematic review and meta⁃analysis[J]. Gastroenterology, 2020,158(6):1554⁃1573.e12. doi: 10.1053/j.gastro.2020.01.001. |
[14] | Diez⁃Domingo J, Parikh R, Bhavsar AB, et al. Can COVID⁃19 increase the risk of herpes zoster? a narrative review[J]. Dermatol Ther (Heidelb), 2021,11(4):1119⁃1126. doi: 10.1007/s13555⁃021⁃00549⁃1. |
[15] | Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia[J]. N Engl J Med, 2014,371(16):1526⁃1533. doi: 10.1056/NEJMcp1403062. |
[16] | Mittal A, Srivastava A, Balai M, et al. A study of postherpetic pruritus[J]. Indian Dermatol Online J, 2016,7(4):343⁃344. doi: 10.4103/2229⁃5178.185479. |
[17] | Kim YJ, Lee CN, Lee MS, et al. Recurrence rate of herpes zoster and its risk factors: a population⁃based cohort study[J]. J Korean Med Sci, 2019,34(2):e1. doi: 10.3346/jkms.2019.34.e1. |
[18] | Stratman E. Visceral zoster as the presenting feature of disseminated herpes zoster[J]. J Am Acad Dermatol, 2002,46(5):771⁃774. doi: 10.1067/mjd.2002.119091. |
[19] | Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia[J]. J Dtsch Dermatol Ges, 2020,18(1):55⁃78. doi: 10.1111/ddg.14013. |
[20] | 曾永芬, 金毅. 带状疱疹后神经痛发病危险因素研究进展[J]. 中国疼痛医学杂志, 2020,26(8):603⁃607. doi: 10.3969/j.issn.1006⁃9852.2020.08.009. |
[21] | Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia[J]. Cochrane Database Syst Rev, 2014,(2):CD006866. doi: 10.1002/14651858.CD006866.pub3. |
[22] | Lamoureux C, Flatrès C, Vallet S, et al. Aseptic meningitis caused by the Varicella⁃zoster virus after primary infection in an immunocompetent child: a case report[J]. Ann Biol Clin (Paris), 2018,76(2):234⁃236. doi: 10.1684/abc.2018.1331. |
[23] | 杨慧兰. 带状疱疹中国专家共识解读[J]. 中华皮肤科杂志, 2018,51(9):699⁃701. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 09.021. |
[24] | Cunningham AL, Breuer J, Dwyer DE, et al. The prevention and management of herpes zoster[J]. Med J Aust, 2008,188(3):171⁃176. doi: 10.5694/j.1326⁃5377.2008.tb01566.x. |
[25] | Werner RN, Nikkels AF, Marinović B, et al. European consensus⁃based (S2k) Guideline on the Management of Herpes Zoster ⁃ guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment[J]. J Eur Acad Dermatol Venereol, 2017,31(1):20⁃29. doi: 10.1111/jdv.13957. |
[26] | Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment[J]. Korean J Pain, 2015,28(3):177⁃184. doi: 10.3344/kjp.2015.28.3.177. |
[27] | Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients[J]. Int J Antimicrob Agents, 1994,4(4):241⁃246. doi: 10.1016/0924⁃8579(94)90024⁃8. |
[28] | Ono F, Yasumoto S, Furumura M, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster[J]. J Dermatol, 2012,39(11):902⁃908. doi: 10.1111/j.1346⁃8138.2012.01584.x. |
[29] | Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster[J]. J Microbiol Immunol Infect, 2001,34(2):138⁃142. |
[30] | Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia[J]. Antiviral Res, 2003,59(1):57⁃60. doi: 10.1016/s0166⁃3542(03)00064⁃0. |
[31] | Watanabe D, Mizukami A, Holl K, et al. The potential public health impact of herpes zoster vaccination of people aged ≥ 50 years in Japan: results of a Markov model analysis[J]. Dermatol Ther (Heidelb), 2018,8(2):269⁃284. doi: 10.1007/s13555⁃018⁃0236⁃3. |
[32] | Lapolla W, Digiorgio C, Haitz K, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open⁃label study[J]. Arch Dermatol, 2011,147(8):901⁃907. doi: 10.1001/archdermatol.2011.81. |
[33] | Migita T. Can early administration of pregabalin reduce the incidence of postherpetic neuralgia?[J]. Clin Exp Dermatol, 2014,39(6):755⁃756. doi: 10.1111/ced.12386. |
[34] | Liang L, Li X, Zhang G, et al. Pregabalin in the treatment of herpetic neuralgia: results of a multicenter Chinese study[J]. Pain Med, 2015,16(1):160⁃167. doi: 10.1111/pme.12564. |
[35] | 带状疱疹后神经痛诊疗共识编写专家组. 带状疱疹后神经痛诊疗中国专家共识[J]. 中国疼痛医学杂志, 2016,22(3):161⁃167. doi: 10.3969/j.issn.1006⁃9852.2016.03.001. |
[36] | Chen N, Yang M, He L, et al. Corticosteroids for preventing postherpetic neuralgia[J]. Cochrane Database Syst Rev, 2010,(12):CD005582. doi: 10.1002/14651858.CD005582.pub3. |
[37] | Koshy E, Mengting L, Kumar H, et al. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review[J]. Indian J Dermatol Venereol Leprol, 2018,84(3):251⁃262. doi: 10.4103/ijdvl.IJDVL_1021_16. |
[38] | Kimberlin DW, Jacobs RF, Weller S, et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age[J]. Clin Infect Dis, 2010,50(2):221⁃228. doi: 10.1086/649212. |
[39] | Rao S, Abzug MJ, Carosone⁃Link P, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study[J]. J Pediatr, 2015,166(6):1462⁃1468.e1⁃4. doi: 10.1016/j.jpeds.2015.01.023. |
[40] | De Paschale M, Clerici P. Microbiology laboratory and the management of mother⁃child varicella⁃zoster virus infection[J]. World J Virol, 2016,5(3):97⁃124. doi: 10.5501/wjv.v5.i3.97. |
[41] | Lilie HM, Wassilew S. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster[J]. Drugs Aging, 2003,20(8):561⁃570. doi: 10.2165/00002512⁃200320080⁃00002. |
[42] | 刘巧. 中西医结合皮肤病治疗学[M]. 北京: 人民军医出版社, 2014. |
[43] | Pei W, Zeng J, Lu L, et al. Is acupuncture an effective postherpetic neuralgia treatment? A systematic review and meta⁃analysis[J]. J Pain Res, 2019,12:2155⁃2165. doi: 10.2147/JPR.S199950. |
[44] | 任玲, 王时巧, 王媚. 如意金黄散联合针灸治疗急性带状疱疹的临床观察[J]. 中国中医急症, 2020,29(11):2014⁃2016. doi: 10.3969/j.issn.1004⁃745X.2020.11.037. |
[45] | 邓诗清, 李茜, 陈晓峰, 等. 电针治疗老年带状疱疹的临床疗效研究[J]. 实用中西医结合临床, 2019,19(6):149⁃150,173. doi: 10.13638/j.issn.1671⁃4040.2019.06.078. |
[46] | 李长华, 甄宗礼, 李泳. 物理治疗联合药物治疗带状疱疹疗效分析[J]. 当代医学, 2019,25(31):119⁃121. doi: 10.3969/j.issn. 1009⁃4393.2019.31.047. |
[47] | Chen YT, Wang HH, Wang TJ, et al. Early application of low⁃level laser may reduce the incidence of postherpetic neuralgia (PHN)[J]. J Am Acad Dermatol, 2016,75(3):572⁃577. doi: 10.1016/j.jaad.2016.03.050. |
[48] | 中国医疗保健国际交流促进会皮肤科分会, 中华医学会皮肤性病学分会老年性皮肤病研究中心. 带状疱疹疫苗预防接种专家共识[J]. 中华医学杂志, 2022,102(8):538⁃543. doi: 10. 3760/cma.j.cn112137⁃20210828⁃01958. |
[49] | Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older[J]. N Engl J Med, 2016,375 (11):1019⁃1032. doi: 10.1056/NEJMoa 1603800. |
[50] | Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults[J]. N Engl J Med, 2015,372(22):2087⁃2096. doi: 10.1056/NEJMoa 1501184. |
[1] | 陈启韬 李煜乾 邵光辉 朱晶 朱麒麟 李中明 杜旭峰 范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210803-e20210803. |
[2] | 杨骥 徐欣植 李明. 皮肌炎的早期诊断和内脏损伤早期识别[J]. 中华皮肤科杂志, 2023, 56(2): 161-164. |
[3] | 中华医学会皮肤性病学分会 中国康复医学会皮肤病康复专业委员会 中国中西医结合学会皮肤性病学分会 中国医药教育协会皮肤病专业委员会. 老年带状疱疹诊疗专家共识[J]. 中华皮肤科杂志, 2023, 56(2): 97-104. |
[4] | 杜方智 张栩 王千秋. 猴痘的临床表现与诊疗随访[J]. 中华皮肤科杂志, 2023, 56(1): 76-81. |
[5] | 中华医学会皮肤性病学分会玫瑰痤疮研究中心 中国医师协会皮肤科医师分会玫瑰痤疮专业组. A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识[J]. 中华皮肤科杂志, 2023, 56(1): 16-21. |
[6] | 李巍 李政. 【开放获取】典型与非典型表现的特应性皮炎[J]. 中华皮肤科杂志, 2023, 56(1): 1-4. |
[7] | 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识[J]. 中华皮肤科杂志, 2023, 56(1): 5-15. |
[8] | 杨玉凤 李艳红 王雨辉 闫润润 孙文娟 段毅飞 李妍. 电刺激和重复经颅磁刺激在带状疱疹后神经痛中的应用现状[J]. 中华皮肤科杂志, 2023, 56(1): 86-89. |
[9] | 雷杰豪 洪为松 林福全 胡文婷 许爱娥. 体外培养节段型白癜风样无色素痣皮损黑素细胞及其临床意义[J]. 中华皮肤科杂志, 2022, 55(9): 798-802. |
[10] | 吕莎 王爽 武寒飞 张明瑞 胡馨 李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632. |
[11] | 罗帅寒天 龙海 陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372. |
[12] | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组 中华医学会皮肤性病学分会儿童学组. 【开放获取】特应性皮炎湿包疗法临床应用专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 289-294. |
[13] | 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组 中华医学会皮肤性病学分会儿童学组 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 281-288. |
[14] | 李锁 向睿宇 李志量 荆可 王媛 张寒梅 冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237. |
[15] | 《脓疱型银屑病诊疗中国专家共识(版)》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
|